1 / 27

Clinical Pathology Haematology Case E

Clinical Pathology Haematology Case E. Ainsley McDonald Veronica Nou Poonam Shrestha Mary Tormey. Ms SP, aged 25, has been taking clozapine for 6 months. What is agranulocytosis? Explain what haematological parameters must a pharmacist sight before dispensing clozapine.

tallis
Download Presentation

Clinical Pathology Haematology Case E

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Clinical Pathology Haematology Case E Ainsley McDonald Veronica Nou Poonam Shrestha Mary Tormey

  2. Ms SP, aged 25, has been taking clozapine for 6 months. • What is agranulocytosis? • Explain what haematological parameters must a pharmacist sight before dispensing clozapine. • What other haematological ADRs are associated with clozapine? • Explain whether the same monitoring is required for olanzapine.

  3. What Is Agranulocytosis? • A condition in which there is an insufficient number of white blood cells called neutrophils or granulocytes. • This can be caused by • a failure of the bone marrow to make sufficient neutrophils or • when white blood cells are destroyed faster than they can be produced. • Granulocytopenia; Granulopenia; Neutropenia

  4. Granulocytes are a type of white blood cell. When they are examined under a microscope, they appear to contain granules, or small dark specks. • Neutrophils, basophils, and eosinophils are all types of granulocytes. • These cells are important in the immune system meaning affected people are more susceptible to infections.

  5. What is going on in the body? • The bone marrow contains special cells known as stem cells. • Stem cells may develop into red blood cells, white blood cells, and platelets. • Certain conditions can damage stem cells, or change their environment causing them to stop production. • This may cause a low level of granulocytes in the body or agranulocytosis.

  6. What are the signs and symptoms of the condition? • Someone who has agranulocytosis may develop life-threatening or chronic infections. • Symptoms vary, depending on the type of infection, but may include the following: • Chills • Fever • Sore throat • Ulcers in the mouth, stomach or bowels • Weakness

  7. What are the causes and risks of the condition? • Agranulocytosis can be caused by a number of factors, including: • Autoimmune disorders, or conditions in which the body attacks its own tissues • Chemotherapy • diseases that damage the bone marrow • hereditary disorders • radiation therapy • Certain medications, such as clozapine or carbamazepine

  8. How is the condition diagnosed? • Diagnosis is usually conducted using a complete blood count, or CBC, to measure the level of neutrophils, basophils, and eosinophils. • Genetic testing may be done if heredity is suspected to be the cause. • If blood tests are abnormal, the provider may order a bone marrow biopsy. This test involves inserting a special needle into the hip bone. A sample is taken from the bone marrow.

  9. What are the long-term effects of the condition? • Agranulocytosis increases a person's risk for infections. If white blood cell levels are extremely low, serious bacterial infections can occur. • Can include infections caused by bacteria that usually don't cause any problems in the body. • Infection in the bloodstream, known as sepsis, may lead to life-threatening septic shock. • Increased risk for chronic infections. These can cause organ damage and scarring.

  10. What are the treatments for the condition? • Initial treatment of agranulocytosis often includes the following: • antibiotics to treat or prevent infections • isolation to keep the person from contracting an infection • stopping the medication that is suspected as the cause of the agranulocytosis, which may resolve the problem • Other treatments may be ordered, depending on the cause of the agranulocytosis. These treatments include: • bone marrow transplant • granulocyte-colony-stimulating factors, such as GM-CSFs or G-CSFs, which stimulate the production of granulocytes • matched stem cell transfusions, which replace damaged stem cells

  11. Bone marrow transplant is an effective treatment for some people with agranulocytosis. • More than half of good candidates for bone marrow transplant are cured. • People are good candidates if they meet these criteria: • under the age of 40 years. • good health prior to the transplant. • matched donor, such as a family member.

  12. What happens after treatment for the condition? • Until blood cell counts return to normal, someone who has agranulocytosis is at risk for infection. • Important to avoid risk factors, such as the following: • activities that cause a rapid heartbeat, chest pain, or shortness of breath • excessive exercise • exposure to contagious diseases

  13. Clozapine

  14. What is Clozapine? • Atypical Anti-psychotic. • Used in the treatment of Schizophrenia in patients who have had an inadequate response to at least two other anti-psychotics, or who cannot tolerate the side effects of these.

  15. Warning! • Clozpine can cause agranulocytosis. (Usually reversible on withdrawal of the drug, although can be fatal) • Only patients that have an initial leucocyte count (WBC > 3500mm3 and normal differential blood count) can commence treatment. • This blood test must be performed 10 days prior to starting treatment.

  16. Monitoring • Regular WBC counts and absolute neutrophil counts: • Weekly during the first 18 weeks • At least monthly thereafter • AND for 1 month after complete discontinuation of treatment.

  17. Monitoring (2) • At each check-up flu- like symptoms should be reported (fever, sore- throat) as could be a sign of neutropenia. • An immediate differential blood count must be performed if patient shows signs of illness.

  18. HAEMATOLOGICAL ADRs ASSOCIATED WITH CLOZAPINE

  19. Haematological ADRs associated with Clozapine • Granulocytopenia and Agranulocytosis • Granulocytopenia is defined as a reduced number of blood granulocytes, namely neutrophils, eosinophils, and basophils • Agranulocytosis can prove fatal • Occur within the first 18 weeks of treatment • Withdrawal of the drug is required

  20. Haematological ADRs associated with Clozapine • Leucocytosis and Eosinophilia • in the initial weeks of treatment • Discontinuation of therapy may be warranted in the event of eosinophilia • Discontinue Clozapine if the eosinophil count rises above 3,000/mm3, and to restart therapy only after the eosinophil count has fallen below 1,000/mm3

  21. Haematological ADRs associated with Clozapine • Thrombocytopenia has been reported rarely • reduction in the number of platelets in the blood • results in bleeding into the skin, spontaneous bruising , and prolonged bleeding after injury • recommended to discontinue Clozapine if the platelet count falls below 50,000/mm3

  22. Explain whether the same monitoring is required for olanzapine.

  23. olanzapine • Also an atypical antipsychotic - but of lower efficacy than clozapine • Not associated with agranulocytosis, whereas clozapine has a 1% incidence (TG-P p2) • The only common hematological disturbance associated with olanzapine in clinical trials was eosinophilia (eMims2003) • Rare adverse effect neutropenia (AMH 2003), whereas clozapine has a 2-3 % incidence

  24. olanzapine • Post Marketing surveillance::(APPG 2002) • Hematological adverse effects: • Leucopenia - rare (0.1-0.01%) • Thrombocytopenia - very rare (<0.01%)

  25. olanzapine • Hyperglyceamia may occur in patients who had random BGL at the upper limit of normal - • Check glucose tolerance in patients who gain weight • Increased risk of developing type 2 diabetes while taking olanzapine

  26. olanzapine • For all antipsychotics::(AMH 2003 p669) • Routine FBCs & LFTs are advisable, particularly during the first few months of treatment and are mandatory with clozapine • Monitor weight gain, blood glucose & cholesterol

More Related